2023 annual financial data

Sutro Biopharma, Inc. 2023 Operating margin

Sutro Biopharma, Inc. 2023 operating margin with verified reported values.

Direct answer

Operating margin was -58.07%.

Operating income was -89,278,000 USD and net income was -106,793,000 USD.
Operating cash flow was -111,616,000 USD.

Get free Sutro Biopharma, Inc. email updates.

Bullstory sends one daily email when new analysis or important company news is available.

Verified data

Revenue
153,731,000 USD
Operating income
-89,278,000 USD
Net income
-106,793,000 USD
Operating cash flow
-111,616,000 USD